Photonic Pharma

What Photonic Pharma does

Photonic Pharma LLC is a Minneapolis-based, University of Minnesota spin-out founded in October 2014 that operates in the early-phase drug discovery (Lead Discovery) segment. The company combines structure-based engineering of fluorescent protein biosensors with fluorescence lifetime detection in living cells, claiming a 30-fold increase in precision for high-throughput screening of small-molecule libraries. Its core platform centers on genetically encoded FRET biosensors in HEK293 human cell lines, deployed via two proprietary instruments co-developed with Fluorescence Innovations: the Fluorescence Lifetime Plate Reader (FLT-PR) and the Spectral Unmixing Plate Reader (SUPR).

The company does not sell products at list price. Its revenue model is grant- and collaboration-driven: it has secured four NIH SBIR/Academic Industrial Partnership grants (totaling roughly $1.6M of direct awards plus a $234,000/year NCI subaward) and a multi-year collaboration and license agreement with Bristol-Myers Squibb (2015–2023) for cardiac myosin modulator discovery, which produced a June 2023 joint SLAS Discovery publication. IP is anchored by an Exclusive Patent License Agreement with the University of Minnesota and a portfolio that includes issued US Patents 8,431,356; 10,281,476; and 10,794,898, plus several pending applications.

Photonic Pharma serves two customer segments: pharmaceutical companies seeking high-precision lead discovery against therapeutically important protein targets, and academic collaborators (University of Minnesota, University of Arizona, Rosalind Franklin University) in cardiac, neurological, and oncology therapeutic areas. The company is privately held by founders David D. Thomas and Jennifer J. Thomas with a minority interest held by the University of Minnesota; it has not raised traditional venture capital. In February 2026 it completed its fourth NIH grant subaward and on March 31, 2026 it donated its proprietary plate readers to the UMN Biophysical Technology Center, ending direct commercial use of its core instrumentation.

Name

Photonic Pharma

Legal name

Photonic Pharma LLC

Website

https://photonicpharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Photonic Pharma LLC is a Minneapolis-based University of Minnesota spin-out that applies proprietary fluorescence lifetime detection and engineered FRET biosensors in living cells to enable high-precision, early-phase drug discovery for pharmaceutical companies and academic collaborators.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA), Cellomics & High-Content Screening (HCS) Services (HLAGANAD), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Fluorescence lifetime detection
• High-throughput drug screening
• Small-molecule lead discovery
• FRET-based biosensor assays
• Early-phase pharmaceutical research

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels1 record

Marketing channels1 record

Core offering

Photonic Pharma provides early-phase Lead Discovery services built on a proprietary platform that combines engineered fluorescent protein biosensors with fluorescence lifetime detection in living human (HEK293) cells. The company applies this platform, supported by custom FLT-PR and SUPR plate readers, to high-throughput screening of small-molecule libraries against therapeutically important protein targets for pharmaceutical companies and academic collaborators, claiming a 30-fold improvement in screening precision over conventional methods.

Product overview

Photonic Pharma offers a unified drug discovery platform built around proprietary fluorescence-based screening technology. The core offering consists of Fluorescent Molecular Biosensor Technology and a Fluorescence Lifetime Detection Platform, which together enable high-throughput screening of small-molecule libraries with a claimed 30-fold improvement in precision. The company also provides specialized instruments (FLT-PR and SUPR plate readers) developed in collaboration with Fluorescence Innovations, Inc., for fluorescence lifetime and spectral unmixing measurements in living cells. This integrated approach targets early-phase Lead Discovery for therapeutically important protein targets across cardiac, neurological, and oncological applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Fluorescence Lifetime Plate Reader (FLT-PR) High-throughput fluorescence lifetime plate reader with top-read capability in 1536-well format, dual-laser 473 nm and 532 nm excitation, and dual detection channels optimized for FRET measurement with compound interference correction, used by Photonic Pharma and collaborators for living-cell HTS campaigns.
• Spectral Unmixing Plate Reader (SUPR) Spectral unmixing plate reader with dual-laser capability (473 nm and 532 nm excitation) for fluorescence-based high-throughput screening and spectral FRET measurements in living cells.
• Lead Discovery Collaboration Services Early-phase Lead Discovery research services for pharmaceutical and academic partners, applying Photonic Pharma's proprietary fluorescence lifetime detection platform and engineered FRET biosensors in living human cells to high-throughput screening of small-molecule libraries against therapeutically important protein targets across cardiac, neurological, and oncological indications.

Quantifiable outcome

• 30-fold increase in precision of high-throughput screening of small-molecule libraries
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Rosalind Franklin UniversityminorStrategic or Co-development Partner · 1 January 2021Collaboration partner on NIH SBIR grant (R43AG069582) for Alzheimer's disease treatment, with Grace E. Stutzmann as collaborator.
• University of ArizonaminorStrategic or Co-development Partner · 1 January 2019Collaboration partner on NIH SBIR grant (R43HL162329) for heart failure therapeutics, with MPI Brett Colson as lead investigator from University of Arizona.
• Bristol-Myers Squibb (BMS)coreStrategic or Co-development Partner · 22 December 2015Multi-year collaboration and license agreement (effective December 22, 2015) for drug discovery using Photonic Pharma's proprietary fluorescence lifetime detection platform. Extended multiple times through January 2021. Joint publication in SLAS Discovery (June 2023) on HTS driven by fluorescence lifetime detection of FRET identifying cardiac myosin modulators.
• University of MinnesotacoreStrategic or Co-development Partner · 17 December 2015Exclusive Patent License Agreement with University of Minnesota (December 17, 2015) covering all commercial rights to issued patents and pending applications related to fluorescence methods in high-throughput screening. University holds minority interest in Photonic Pharma. Multiple collaborative research projects including cancer research (R01 CA255513-01).
• Fluorescence Innovations, Inc.coreTechnology or IntegrationStrategic instrumentation collaborator that provides access to unique fluorescence lifetime instrumentation. Collaboratively designed custom FLT plate readers (FLT-PR and SUPR) for commercial HTS applications. FI maintains instruments and ensures optimal configuration.
• University of Minnesota - Biophysical Technology Center (BTC)coreTechnology or IntegrationProvides access to cell culture facilities, liquid handling equipment, and NIH Clinical Collections for pilot screens. Photonic Pharma donated its plate readers to BTC effective March 2026.

Scale indicators5 records

Recent moves10 records

Expansion highlights4 records

Direct peers

• Molecular Devices (Danaher): Major manufacturer of microplate readers and HTS instrumentation used in drug discovery, including fluorescence-based readers that compete with Photonic Pharma's custom FLT-PR and SUPR instruments for cell-based screening workflows.
• Revvity (formerly PerkinElmer / Cisbio): Through its Cisbio legacy HTRF product line, Revvity is the leading commercial provider of FRET-based assay kits for HTS — directly comparable to Photonic Pharma's genetically encoded FRET biosensor technology for drug discovery screening.
• Promega Corporation: Develops and commercializes cell-based luminescent and fluorescent biosensor assays used in pharma HTS and lead discovery, overlapping with Photonic Pharma's focus on genetically encoded reporters in living cells.
• Agilent Technologies (BioTek legacy): Through its BioTek acquisition, Agilent sells a broad line of microplate readers used in cell-based screening — directly comparable to Photonic Pharma's FLT-PR and SUPR plate reader products for fluorescence-based HTS.

Broad incumbents

• Thermo Fisher Scientific: Operates both a large life-sciences instruments business (plate readers, fluorescence tools) and pharma services / PPD CRO organization offering HTS and drug discovery capabilities — a broad incumbent with overlapping platform components.
• Evotec SE: Global contract research organization offering early-phase drug discovery including high-throughput screening, hit identification, and allosteric modulator discovery — comparable in service scope to Photonic Pharma's lead discovery offerings.
• Charles River Laboratories: Major CRO providing early discovery, in vitro pharmacology, and HTS services to pharma and biotech — operating at far greater scale than Photonic Pharma but addressing the same lead-discovery customer needs.
• Eurofins Discovery: Offers comprehensive drug discovery services including assay development, HTS, and medicinal chemistry, competing for the same Big Pharma early-phase discovery budgets as Photonic Pharma.
• Eurofins Panlabs: Discovery services arm of Eurofins offering cell-based assay development and HTS for pharma collaborators — competes with Photonic Pharma for outsourced lead-discovery contracts.

Emerging players

• AAT Bioquest: Specialty supplier of fluorescent probes and assay reagents for high-throughput screening and fluorescence-based detection — comparable as a fluorescent-detection technology provider in the drug discovery tools space.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/photonic-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Photonic Pharma